Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3787766
Max Phase: Preclinical
Molecular Formula: C80H122N24O16
Molecular Weight: 1676.01
Molecule Type: Small molecule
Associated Items:
ID: ALA3787766
Max Phase: Preclinical
Molecular Formula: C80H122N24O16
Molecular Weight: 1676.01
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCCCCCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Standard InChI: InChI=1S/C80H122N24O16/c1-45(2)39-61(73(117)97-55(13-9-35-91-77(83)84)69(113)101-59(67(81)111)41-47-19-27-51(105)28-20-47)103-71(115)57(15-11-37-93-79(87)88)99-75(119)63(43-49-23-31-53(107)32-24-49)95-65(109)17-7-5-6-8-18-66(110)96-64(44-50-25-33-54(108)34-26-50)76(120)100-58(16-12-38-94-80(89)90)72(116)104-62(40-46(3)4)74(118)98-56(14-10-36-92-78(85)86)70(114)102-60(68(82)112)42-48-21-29-52(106)30-22-48/h19-34,45-46,55-64,105-108H,5-18,35-44H2,1-4H3,(H2,81,111)(H2,82,112)(H,95,109)(H,96,110)(H,97,117)(H,98,118)(H,99,119)(H,100,120)(H,101,113)(H,102,114)(H,103,115)(H,104,116)(H4,83,84,91)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
Standard InChI Key: LJIWUPHPKKONTE-ZCWJDUOTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1676.01 | Molecular Weight (Monoisotopic): 1674.9471 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kuhn KK, Ertl T, Dukorn S, Keller M, Bernhardt G, Reiser O, Buschauer A.. (2016) High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling., 59 (13): [PMID:27223253] [10.1021/acs.jmedchem.6b00309] |
Source(1):